Abstract
Coronary heart disease (CHD) is the leading cause of death in the developed world in both men and women. Elevated low-density lipoprotein cholesterol (LDL-C) levels are strong and independent vascular risk factors in both genders. Statins effectively decrease LDL-C levels, reduce vascular morbidity and mortality and are an essential component of CHD preventive strategies. However, women are less likely to be prescribed statins than men in both primary and secondary prevention settings. It was argued that there is no conclusive evidence showing that statins are beneficial for the prevention of vascular disease in women, particularly in those without established CHD. This review summarizes the evidence regarding the effects of statins in the prevention of CHD in women. Accumulating data suggest that statins are equally effective in both men and women. The lack of significant effects in some studies appears to be primarily due to the under-representation of women and the ensuing lack of statistical power. Current guidelines for the prevention of vascular disease also recommend a similar management of dyslipidemia in both men and women. Therefore, statin treatment should be implemented with the same criteria and with the same goals in both genders.
Current Pharmaceutical Design
Title: The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Volume: 15 Issue: 10
Author(s): Konstantinos Tziomalos, Anna I. Kakafika, Vasilios G. Athyros, Asterios Karagiannis and Dimitri P. Mikhailidis
Affiliation:
Abstract: Coronary heart disease (CHD) is the leading cause of death in the developed world in both men and women. Elevated low-density lipoprotein cholesterol (LDL-C) levels are strong and independent vascular risk factors in both genders. Statins effectively decrease LDL-C levels, reduce vascular morbidity and mortality and are an essential component of CHD preventive strategies. However, women are less likely to be prescribed statins than men in both primary and secondary prevention settings. It was argued that there is no conclusive evidence showing that statins are beneficial for the prevention of vascular disease in women, particularly in those without established CHD. This review summarizes the evidence regarding the effects of statins in the prevention of CHD in women. Accumulating data suggest that statins are equally effective in both men and women. The lack of significant effects in some studies appears to be primarily due to the under-representation of women and the ensuing lack of statistical power. Current guidelines for the prevention of vascular disease also recommend a similar management of dyslipidemia in both men and women. Therefore, statin treatment should be implemented with the same criteria and with the same goals in both genders.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Kakafika I. Anna, Athyros G. Vasilios, Karagiannis Asterios and Mikhailidis P. Dimitri, The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women, Current Pharmaceutical Design 2009; 15 (10) . https://dx.doi.org/10.2174/138161209787846946
DOI https://dx.doi.org/10.2174/138161209787846946 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Current Cardiology Reviews The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease
Current Drug Metabolism Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine
Current Vascular Pharmacology Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Effect of Immunoglobulin Therapy on Blood Viscosity and potential concerns of Thromboembolism, Especially in Patients with Acute Kawasaki Disease
Recent Patents on Cardiovascular Drug Discovery Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Chemometric Assisted Simultaneous Analysis of Verapamil Hydrochloride, Gliclazide and Simvastatin in Bulk Drug and Fixed Dose Combinatinos (polypill) - A Futuristic Approach
Current Analytical Chemistry Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Menopause, A Universal Female Experience: Lessons from Mexico and Central America
Current Women`s Health Reviews Recent Developments in PET Instrumentation
Current Pharmaceutical Biotechnology Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment
Current Pharmaceutical Design Benefits of Olive Oil Phenolic Compounds in Disease Prevention
Endocrine, Metabolic & Immune Disorders - Drug Targets Treasures Hunt in Old Mines: Terminalia chebula-Based Traditional Herbal Medicinal Products
The Natural Products Journal Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals